Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.54 |
| ▸ | FNTB | P49356 | 19/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.45 |
| ▸ | NRAS | P01111 | 1/20 | 0.45 |
| ▸ | HRAS | P01112 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7656500 | 0.84 | FNTA (0.72) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL5891552 | 0.83 | FNTA (0.74) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7659750 | 0.77 | FNTA (0.69) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL3499362 | 0.77 | FNTA (0.42) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL5891602 | 0.76 | FNTA (0.68) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL7182161 | 0.76 | FNTA (0.68) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL7656506 | 0.72 | FNTA (0.45) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL3499938 | 0.71 | FNTA (0.84) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL3499935 | 0.71 | FNTA (0.84) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL9083888 | 0.70 | FNTA (0.83) | FNTAFNTBPGGT1BNRASHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | claimed |
| US-6387903-B1 | ANTICANCER AGENT; CARDIOVASCULAR DISORDERS; VIRICIDES | MERCK & CO., INC. | 2002-05-14 | — | — | US | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| US-6387903-B1 | ANTICANCER AGENT; CARDIOVASCULAR DISORDERS; VIRICIDES | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885PGGT1B 191/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885PGGT1B 2532/4885 |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, NLN | FNTA 12/4885FNTB 44/4885PGGT1B 1996/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885PGGT1B 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.